Percutaneous penetration of fluorescein isothiocyanate-dextrans and the mechanism for enhancement effect of enhancers on the intercellular penetration.
To identify the mechanism involved in the enhancement effect of enhancers on the intercellular penetration of large polar molecules, the skin penetration of fluorescein isothiocyanate (FITC)-dextrans (average molecular weight; 4400, 9400, and 69000 Da) and the lipid removal from the intercellular spaces by enhancers were studied using hairless rat skin. Pretreatment of hairless rat skin with enhancers such as n-octanol (20%), laurocapram (2%), isopropylmyristate (IPM, 20%), oleic acid (5%) and cineol (2%), which are water-immiscible, significantly enhanced the flux of FITC-dextrans, while pretreatment with water-miscible enhancers, i.e. dimethyl sulfoxide (DMSO, 5%) and N-methyl-2-pyrrolidone (NMP) did not increase the flux compared with the control. The penetration of FITC-dextrans was approximately size dependent. n-Octanol, laurocapram, IPM and oleic acid dramatically removed ceramides which are the intercellular lipids, whereas NMP and DMSO partly extracted the sphingolipids. A linear relationship was observed between the flux and removal of ceramides (p < 0.01), indicating that the removal of intercellular lipids would cause dramatic dilations between adherent cornified cells and enhance the penetration through the intercellular pathways. When the penetration of FITC-dextrans through Wistar rat skin was compared with that via hairless rat skin, the steady state flux of FITC-dextrans through Wistar rat skin pretreated with water-immiscible enhancers was 1.2- to 4.9-fold higher, suggesting that the penetration of large polar molecules through follicles may play at least some role in the percutaneous absorption.
Ogiso
T
T
Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.
Paku
T
T
Iwaki
M
M
Tanino
T
T
D000818:Animals; D001381:Azepines / Q000494:pharmacology; D002518:Ceramides / Q000737:chemistry; D003511:Cyclohexanols; D003911:Dextrans / Q000493:pharmacokinetics*; D004817:Epidermis / Q000737:chemistry / Q000378:metabolism; D000431:Ethanol / Q000494:pharmacology; D000077591:Eucalyptol; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D008055:Lipids / Q000737:chemistry; D008297:Male; D008610:Menthol / Q000031:analogs & derivatives / Q000494:pharmacology; D039821:Monoterpenes; D009226:Myristates / Q000494:pharmacology; D019301:Oleic Acid; D009829:Oleic Acids / Q000494:pharmacology; D010592:Pharmaceutic Aids / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012867:Skin / Q000737:chemistry; D012869:Skin Absorption / Q000187:drug effects*; D013107:Sphingolipids / Q000737:chemistry; D013729:Terpenes
D001381:Azepines; D002518:Ceramides; D003511:Cyclohexanols; D003911:Dextrans; D008055:Lipids; D039821:Monoterpenes; D009226:Myristates; D009829:Oleic Acids; D010592:Pharmaceutic Aids; D013107:Sphingolipids; D013729:Terpenes; C015219:fluorescein isothiocyanate dextran; C008205:isopropyl myristate; D008610:Menthol; C035229:laurocapram; D019301:Oleic Acid; D000431:Ethanol; D016650:Fluorescein-5-isothiocyanate; D000077591:Eucalyptol